Top marks for Cherwell’s Redipor prepared microbial media products
Extensive range of ready-to-use culture media available in bottles and plates.
A recent customer satisfaction survey has affirmed that the vast majority would recommend Cherwell and its Redipor microbiological media products to a colleague. Value for money, excellent customer service and product quality were all key factors contributing to the very positive outcome of this survey. These results are evidenced by Redipor’s growing user base within the pharmaceutical and associated industries both domestically and across Europe. Therefore, to accommodate all customers, Cherwell has just released both UK and Euro versions of its 2018/19 Redipor Prepared Media price list, now available to download from Cherwell’s website.
Redipor prepared media products scored highly with customers in Cherwell’s recent survey to achieve an impressive Net Promoter Score of +76 (from a range of -100 to +100). Customer comments as to ‘Why Cherwell?’ included: ”The excellent service; great pricing; exceeding expectations with delivery times; helping us out in a crisis; flexibility by preparing bespoke media; pragmatic advice; and realistic timeframes. What more could anyone want?”
Meeting varying customer needs, such as for environmental monitoring, sterility testing and validation applications, the new Redipor price list details the extensive range of ready-to-use culture media available in bottles and plates. Cherwell provides a selection of the most commonly requested types, many of which are available from stock for next day delivery. In addition to those included in the price list, Cherwell offers many other bespoke products which are made to order with short lead times and small minimum order requirements. Discounts are available for high volume and standing orders.
“With customer satisfaction and ease of access in mind, we have laid out our new Redipor price list to enable straightforward reference of ordering information and products,” said Andrew Ramage, Cherwell’s Microbiology Product Specialist. “And if customers can't find exactly what they need, we’d like to hear from them as we frequently adapt to meet specific requirements, be it the media formulation, format, packaging or quantity. We are also very happy to provide rapid quotations and flexible delivery schedules.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...